Lenalidomide

• A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T… Ended
  2022-501346-30-00 Phase III 12 countries Celgene Corp.
• A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in comb… Ended
  2024-517723-39-00 Phase II 1 country Hellenic Society Of Hematology
• An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab… Ended
  2024-514016-26-00 Phase II 1 country Fundacion Pethema
• International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab Ended
  2023-507180-19-00 Phase II 7 countries Sanofi-Aventis Recherche & Developpement
• A Clinical Study to evaluate the long-term safety of Daratumumab in combination with standard bone marrow cancer treatment regiments Ended
  2022-500138-27-01 Phase III 9 countries Janssen - Cilag International
• A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L… Ended
  2024-511594-30-00 Phase III 4 countries Kite Pharma Inc.
• This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in… Ended
  2023-505628-67-00 Phase III 14 countries AbbVie Deutschland GmbH & Co. KG
• A Phase 3 study of Tafasitamab plus Lenalidomide in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Ended
  2023-505579-53-00 Phase III 10 countries Incyte Corp.
• Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended
  2024-517008-12-00 Phase III 1 country Fundacion PETHEMA
• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended
  2023-508897-27-00 Phase III 14 countries Pfizer Inc.
• Belantamab Mafodotin in combination with Daratumumab, Lenalidomide and Dexamethasone for the treatment of patients with newly diagnosed mul… Ended
  2024-515634-32-00 Phase I/II 1 country Hellenic Society Of Hematology
• A Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide in Patients with … Ended
  2023-507993-42-00 Phase I/II 5 countries Incyte Corp.
• Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuxima… Ended
  2024-512749-18-00 Phase II 2 countries Cancer Trials Ireland
• PCL-2 - PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION (… Ended
  2024-515037-15-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif… Ended
  2023-507286-25-00 Phase II 2 countries LYSARC
• A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Len… Ended
  2023-505850-16-00 Phase III 16 countries Janssen - Cilag International
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr… Ended
  2023-504684-16-00 Phase III 16 countries Incyte Corp.
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended
  2022-500237-92-00 Phase III 11 countries Incyte Corp.
• A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in comb… Ended
  2024-515988-55-00 Phase II 1 country Hellenic Society Of Hematology
• Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Ended
  2023-503384-41-00 Phase III 7 countries Seagen Inc.
• A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenal… Ended
  2024-513422-38-00 Phase III 8 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• A Study Evaluating the Safety, Pharmacokinetics (what the body does to a drug), and Efficacy of Mosunetuzumab given subcutaneously (SC) or i… Ended
  2023-507236-20-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
• Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma Ended
  2023-507419-37-00 Phase III 11 countries Sanofi-Aventis Recherche & Developpement
• An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma Ended
  2023-506587-13-00 Phase II 5 countries Janssen - Cilag International

Showing 49–72 of 97 trials